SCOTUS imposes new limits on assignor estoppel

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

SCOTUS imposes new limits on assignor estoppel

adobestock-87599523.jpeg

In a five to four ruling, the US Supreme Court upheld the doctrine of assignor estoppel but said it could only be used in certain instances

The US Supreme Court upheld the doctrine of assignor estoppel today, June 29, but imposed new limits on when it could be used.

In a five to four decision in Minerva v Hologic, the high court ruled that while there are valid uses for the doctrine – which bars inventors from challenging their own patents today – it has been applied in the past to improperly stop warranted challenges to patent validity.

Justice Elena Kagan, who wrote the majority opinion, said the doctrine applies only when an inventor says one thing (explicitly or implicitly) in assigning a patent and the opposite in litigating against the patent’s owner.

Stefan Szpajda, partner at Dorsey & Whitney in Seattle, said: “The Supreme Court’s ruling honours the centuries-old fairness principles on which assignor estoppel is based, while acknowledging the practical contemporary reality of how patents are invented, assigned, and later sold.

“The majority’s ruling will be seen as a win for competition and employee mobility, as it will make it harder for companies to rely on assignor estoppel to shield their patents from challenge by competitors who hire their former employees.”

This issue of assignor estoppel arose in the case after Hologic, a medical devices company, sued uterine health specialist Minerva for infringing certain claims of its US patents (6,872,183 and 9,095,348). Hologic had acquired the rights indirectly from the founder of Minerva, Csaba Truckai.

Minerva asserted invalidity arguments and filed inter partes reviews at the Patent Trial and Appeal Board (PTAB), before Hologic responded by asserting assignor estoppel.

The PTAB decided that the method patent claims were invalid, and Minerva asked the District Court for the District of Delaware to dismiss the asserted claims from those patents as moot. The district court denied the request because the claims had not yet been cancelled and were still subject to appeal.

Hologic then moved for summary judgment at the district court, which granted the motion and agreed with the company that assignor estoppel barred Minerva from asserting invalidity.

After the trial, the Court of Appeals for the Federal Circuit affirmed the PTAB’s final written decision concerning the unpatentability of the method patent claims.

As a result, the district court denied Hologic's motion for a permanent injunction and for supplemental damages. Hologic and Minerva appealed to the Federal Circuit.

On appeal, the appellate court affirmed-in-part and vacated-in-part the District of Delaware's judgment, and remanded the case.

Both parties ended up appealing to SCOTUS. The high court accepted the petition for writ of certiorari from Minerva on January 8, but denied Hologic’s petition.



more from across site and SHARED ros bottom lb

More from across our site

The IP services provider is targeting further expansion as cost and efficiency pressures push law firms and in-house teams to rethink how they manage global portfolios
Two experienced UPC practitioners join the UK IP boutique’s growing German operation, with further recruitment planned as the firm expands in Europe
The Australian IP firm is taking on bigger rivals in Southeast Asia, betting that agility and transparent pricing can help it stand out
The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Gift this article